Q1 2023 Results
Company overview
Innovation: Pipeline overview
Financial review
Financial performance
Cardiovascular
Immunology
Ophthalmology
cipargamin - PfATP4 inhibitor
Conclusions
NCT04675931 KARISMA (CKAE609B12201)
Malaria severe
Indication
Phase
Phase 2
Patients
252
Primary
Outcome
Measures
Arms
Intervention
Percentage of participants achieving at least 90% reduction in Plasmodium
falciparum (P. falciparum) at 12 hours [ Time Frame: Day 1 (12 Hours) ]
Arm 1: experimental, IV KAE609 Dose regimen 1
Arm 2: experimental, IV KAE609 Dose regimen 2
Arm 3: experimental, IV KAE609 Dose regimen 3
Arm 4: active comparator, IV Artesunate
Arm 5: Coartem, Standard of care
Patients with Malaria, severe
Target
Patients
Readout
Milestone(s)
Publication
2024
TBD
Neuroscience
Global Health
Appendix
References
Innovation: Clinical trials
Abbreviations
Oncology
Other
Biosimilars
88 Investor Relations | Q1 2023 Results
1 NOVARTIS | Reimagining MedicineView entire presentation